36results about How to "Significantly effective" patented technology

A biomarker generator system for producing approximately one (1) unit dose of a biomarker. The biomarker generator system includes a small, low-power particle accelerator (“micro-accelerator”) and a radiochemical synthesis subsystem having at least one microreactor and / or microfluidic chip. The micro-accelerator is provided for producing approximately one (1) unit dose of a radioactive substance, such as a substance that emits positrons. The radiochemical synthesis subsystem is provided for receiving the radioactive substance, for receiving at least one reagent, and for synthesizing the approximately one (1) unit dose of a biomarker.

A biomarker generator system for producing approximately one (1) unit dose of a biomarker. The biomarker generator system includes a small, low-power particle accelerator (“micro-accelerator”) and a radiochemical synthesis subsystem having at least one microreactor and / or microfluidic chip. The micro-accelerator is provided for producing approximately one (1) unit dose of a radioactive substance, such as a substance that emits positrons. The radiochemical synthesis subsystem is provided for receiving the radioactive substance, for receiving at least one reagent, and for synthesizing the approximately one (1) unit dose of a biomarker.

Techniques are disclosed for reducing scan times in mass spectral tissue imaging studies. According to a first technique, a tissue imaging boundary is defined that closely approximates the edges of a tissue sample. According to a second technique, a low-resolution scan is performed to identify one or more areas of interest within the tissue sample, and the identified areas of interest are subsequently scanned at higher resolution.

This specification relates to an improved method, process and apparatus for disinfecting and sterilizing all types of surfaces and indoor air and room air contaminated with microorganisms. The improved apparatus consists of a multi-wavelength narrow spectral width UV source that is more effective than mercury based 254 nm germicidal lamps for destroying the DNA and outer shell or membrane of virus, bacteria, spores and cists.

Techniques are disclosed for reducing scan times in mass spectral tissue imaging studies. According to a first technique, a tissue imaging boundary is defined that closely approximates the edges of a tissue sample. According to a second technique, a low-resolution scan is performed to identify one or more areas of interest within the tissue sample, and the identified areas of interest are subsequently scanned at higher resolution.

A low-volume biomarker generator for producing ultra-short lived radiopharmaceuticals. The low-volume biomarker generator system includes a low-power cyclotron and a radiochemical synthesis system. The cyclotron of the low-volume biomarker generator is optimized for producing radioisotopes useful in synthesizing radiopharmaceuticals in small quantities down to approximately one (1) unit dose. The cyclotron incorporates permanent magnets in place of electromagnets and / or an improved rf system to reduce the size, power requirements, and weight of the cyclotron. The radiochemical synthesis system of the low-volume biomarker is a small volume system optimized for synthesizing the radiopharmaceutical in small quantities of approximately one (1) unit dose.

A microfluidic radiopharmaceutical production system and process for synthesizing per run approximately, but not less than, one (1) unit dose of a radiopharmaceutical biomarker for use in positron emission tomography (PET). The radiopharmaceutical production system includes a reaction vessel that receives a radioisotope from an accelerator or other radioisotope generator. Organic and aqueous reagents are introduced into the reaction vessel, and the mixture is heated to synthesize a solution of a pre-selected radiopharmaceutical. The radiopharmaceutical solution is purified by passing the solution through a solid phase extraction column and a filter. The synthesis process produces per run a quantity of radiopharmaceutical approximately equal to, but not less than, one (1) unit dose of a radiopharmaceutical, reducing waste and allowing for the production of radiopharmaceutical on an as-needed basis. The synthesis process allows for the production of biomarker radiopharmaceuticals on site and close to the location where the unit dose will be administered to the patient. On-site, as-needed production of radiopharmaceuticals in small doses reduces the time between the synthesis of the radiopharmaceutical and the administration of that radiopharmaceutical, thereby minimizing the loss of active isotopes through decay and allowing the production of lesser amounts of radioisotopes overall.

This specification relates to an improved method, process and apparatus for disinfecting and sterilizing all types of surfaces and indoor air and room air contaminated with microorganisms. The improved apparatus consists of a multi-wavelength narrow spectral width UV source that is more effective than mercury based 254 nm germicidal lamps for destroying the DNA and outer shell or membrane of virus, bacteria, spores and cists.

A system for analyzing a business process integration and management (BPIM) solution includes an assembler which assembles a plurality of solution artifacts to form a platform independent solution template, a simulator which simulates an execution of a BPIM solution based on the platform independent solution template, and an analyzer for analyzing a performance of the BPIM solution.

A composition for preventing or treating an eye disease includes adiponectin as an active ingredient. Adiponectin as an active ingredient is eventually revealed to show prevention or therapeutic efficacies for eye diseases such as dry eye (syndrome), inflammatory eye disease and side effects due to the use of contact lenses by promoting tear secretion, alleviating ocular surface irregularities, decreasing inflammatory cytokines on the ocular surface and lacrimal gland, and increasing conjunctival goblet cell density. In addition, the composition having eye contact lubrication effects may be used as cleaners or lubricants for preventing non-bacterial inflammation due to wearing contact lenses.

A microfluidic radiopharmaceutical production system and process for synthesizing per run approximately, but not less than, one (1) unit dose of a radiopharmaceutical biomarker for use in positron emission tomography (PET). The radiopharmaceutical production system includes a reaction vessel that receives a radioisotope from an accelerator or other radioisotope generator. Organic and aqueous reagents are introduced into the reaction vessel, and the mixture is heated to synthesize a solution of a pre-selected radiopharmaceutical. The radiopharmaceutical solution is purified by passing the solution through a solid phase extraction column and a filter. The synthesis process produces per run a quantity of radiopharmaceutical approximately equal to, but not less than, one (1) unit dose of a radiopharmaceutical, reducing waste and allowing for the production of radiopharmaceutical on an as-needed basis. The synthesis process allows for the production of biomarker radiopharmaceuticals on site and close to the location where the unit dose will be administered to the patient. On-site, as-needed production of radiopharmaceuticals in small doses reduces the time between the synthesis of the radiopharmaceutical and the administration of that radiopharmaceutical, thereby minimizing the loss of active isotopes through decay and allowing the production of lesser amounts of radioisotopes overall.

An automated HPLC-based quality control system to perform quality control testing on a radiopharmaceutical solution shortly after synthesis. An automated HPLC-based quality control system makes efficient use of sample volume and is compatible with a variety of radioisotopes and radiopharmaceutical compounds. In several embodiments, the automated nature of an automated HPLC-based quality control system allows for quality control tests to be conducted quickly and with minimal impact on user workflow. When used as part of an integrated PET biomarker radiopharmaceutical production system, the present general inventive concept permits a manufacturer to produce product and conduct quality control tests with lower per dose costs and shorter testing times.

High-power inductively coupled plasma technology is used for thermal cracking and vaporization of continuously fed carbonaceous materials into elemental carbon, for reaction with separate and continuously fed metal catalysts inside a gas-phase high-temperature reactor system operating at or slightly below atmospheric pressures. In one particularly preferred embodiment, in-flight growth of carbon nanomaterials is initiated, continued, and controlled at high flow rates, enabling continuous collection and product removal via gas / solid filtration and separation methods, and / or liquid spray filtration and solid collection methods suitable for producing industrial-scale production quantities. In another embodiment, the reaction chamber and / or filtration / separation media include non-catalytic or catalytic metals to simultaneously or separately induce on-substrate synthesis and growth of carbon nanomaterials. The on-substrate grown carbon nanomaterials are produced in secondary chambers that are selectively isolated for periodic removal of the product.

A low-volume biomarker generator for producing ultra-short lived radiopharmaceuticals. The low-volume biomarker generator system includes a low-power cyclotron and a radiochemical synthesis system. The cyclotron of the low-volume biomarker generator is optimized for producing radioisotopes useful in synthesizing radiopharmaceuticals in small quantities down to approximately one (1) unit dose. The cyclotron incorporates permanent magnets in place of electromagnets and / or an improved rf system to reduce the size, power requirements, and weight of the cyclotron. The radiochemical synthesis system of the low-volume biomarker is a small volume system optimized for synthesizing the radiopharmaceutical in small quantities of approximately one (1) unit dose.